HS-110 (viagenpumatucel-L) is our first biologic product candidate in a series of proprietary ImPACT® based immunotherapies designed to stimulate a patient’s own T-cells to destroy cancer.
| Program | Mechanism of Action (Modality) |
Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
HS-110 |
gp96 + CTAs (Cell Therapy) |
NSCLC |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
CTA = Cancer testis antigens; NSCLC = Non-small cell lung cancer
Using our gp96 platform, the company has developed HS-110 as a treatment for patients with non-small cell lung cancer.
HS-110 is an off-the-shelf cell-based therapy. Our scientists have genetically engineered HS-110 to secrete a wide range of cancer testis antigens chaperoned by gp96 proteins.
In clinical trials, HS-110 demonstrated a broad activation of T-cell mediated immune response in cancer patients.
Our HS-110 Phase 2, multicenter clinical trial is evaluating the safety and efficacy of HS-110 in combination with Bristol-Myers Squibb’s checkpoint inhibitor, nivolumab (Opdivo®) or Merck’s checkpoint inhibitor, pembrolizumab (Keytruda®). The enrollment for this trial has completed with approximately 120 patients.
Positive interim results have been presented at leading medical conferences including American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR) and Society for Immunotherapy of Cancer (SITC).
Visit www.clinicaltrials.gov for more details.
VISIT WWW.CLINICALTRIALS.GOV FOR MORE DETAILS
The HS-110 product used in our clinical trials is manufactured under cGMP guidelines. The cell line is grown in large quantities, dispensed into individual doses, frozen in liquid nitrogen, irradiated to render cell replication incompetent and quality tested in compliance with FDA guidelines.
